Abstract. Vitexin, a lignan compound, has been shown to exert apoptotic actions on human breast cancer cell lines and to have anti-inflammatory activities. Nevertheless, there is currently no study addressing the effects of vitexin on the induction of apoptosis in U937 human leukemia cells. The aim of this study was to determine the anticancer effects and molecular mechanisms of vitexin on U937 leukemia cells. We showed that vitexin can potently induce programmed cell death in U937 leukemia cell growth as well as morphological changes that were examined by MTT assay and phase contrast microscopy, respectively. The DNA content and the levels of mitochondrial membrane potential (∆Ψm) were determined by flow cytometric analysis. The cell cycle arrest-regulated and apoptosis-associated protein levels were measured by western blotting. Vitexin-triggered apoptosis was accompanied by a decrease of the level of ∆Ψm and the percentage of viability and provoked apoptosis in U937 cells. The downregulation of the protein level for Bcl-2 with the simultaneous upregulation of caspase-3 and -9 protein expression in U937 cells were observed after treatment with vitexin. Therefore, our data provide a potential mechanism for the chemopreventive activity of vitexin, and we suggest that vitexin may serve as a therapeutic agent for the treatment of human leukemia.
Introduction
Approximately four per 100,000 people succumb to leukemia each year in Taiwan, according to reports from the Department of Health, Executive Yuan of Taiwan (1, 2) . The current primary treatment for leukemia is chemotherapy, however the survival rates remain unsatisfactory. Acute myeloid leukemia (AML) increases the number of myeloid cells in the bone marrow and interrupts their maturation, resulting in hematopoietic insufficiency (3) (4) (5) . Differentiation induction, as a therapeutic strategy, can have a powerful impact on hematopoietic malignancies, in particular on myeloid leukemia (6, 7) . Therefore, discovering a new antileukemia agent that is more effective and less toxic for leukemia patients is necessary.
Vitexin is a natural apigenin flavone glucoside, found in the Desmodium species (8, 9) . It has been reported to exhibit biological activities, including antioxidant and antiinflammatory effects (8) . Vitexin is now known to also possess antitumor activities by targeting apoptotic cell death in human breast cancer cell lines and potent inhibition on tumor necrosis factor α (TNF-α)-induced cell death (10) . Therefore, our study investigated the effects of vitexin on the induction of apoptosis in U937 human leukemia cells.
Apoptosis assures the homeostasis of tissues during development, host defense and aging (11, 12) . Divergent cell survival due to insufficient apoptosis has been linked to the development and/or progression of human malignancies (13) . Nevertheless, cancer cells with mutations or abnormalities in the expression of other genes that regulate apoptosis can display intrinsic resistance to chemotherapy-induced apoptosis (11, 14) . This suggests that acquired defects in the apoptotic process play an important role in the development of drug resistance. In addition, several transcription factors have been shown to be targets of vitexin action, which may mediate vitexin-induced programmed cell death (15) . This study investigated whether vitexin could induce cell apoptosis in U937 human leukemia cells, as there is currently no available information regarding its cytotoxic effects on human leukemia cells.
Materials and methods
Chemicals and reagents. Vitexin (Fig. 1) , dimethylsulfoxide (DMSO), propidium iodide (PI), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), RNase A, Triton X-100 and cyclosporine A were purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA). All primary and secondary antibodies were obtained from Santa Cruz Biotechnology Inc., (Santa Cruz, CA, USA). TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.6), potassium phosphates and z-VAD were purchased from Merck Co. (Darmstadt, Germany). RPMI-1640 medium, fetal bovine serum (FBS), penicillin-streptomycin and L-glutamine were obtained from Gibco/Life Technologies (Grand Island, NY, USA). All of the chemicals used were of reagent grade.
Cell cultures. The human lymphoma U937 cell line was purchased from the Food Industry Research and Development Institute (Hsinchu, Taiwan, R.O.C.). The cells were grown in RPMI-1640 medium supplemented with 10% heat-inactivated FBS, 100 µg/ml penicillin-100 U/ml streptomycin and 2 mM L-glutamine, and grown in a humidified 5% CO 2 atmosphere at 37˚C. The cells were subcultured every third day (16) .
Cell viability and morphological changes. The U937 human leukemia cells were placed in 96-well cell culture plates at an initial concentration of 1x10 4 cells/ml and incubated with various concentrations of vitexin (0, 50, 100, 200 and 400 µM). After a 24-h incubation period, MTT solution (0.5 mg/ml) was added into the wells for 4 h. The growth medium was removed, and the formazan crystals formed by oxidation of the MTT dye were dissolved with 100 µl 0.04 N HCl in isopropanol. The absorbance was measured at 570 nm by ELISA reader and the cell survival ratio was expressed as a percentage of the control as previously described (17, 18) . For morphological changes, cells were cultured in 12-well plates at a density of 2x10 5 cells/well and treated with or without 200 µM of vitexin for 24 h. Morphological changes in vitexin-treated cells were examined and photographed using phase-contrast light micro scopy (19) . All results were obtained from three independent experiments.
DNA laddering fragmentation assay. Approximately 2x10 5 cells/well of U937 cells were grown in 12-well plates and treated with vitexin or vitexin plus z-VAD (a pan-caspase inhibitor) for 24 h. DNA was extracted from vitexin-treated and untreated cells with the Tissue and Cell Genomic DNA purification kit (Genemark Technology Co., Ltd. Tainan, Taiwan). DNA fragmentation was visualized by 1.5% agarose gel electrophoresis as previously described (20, 21) .
Flow cytometric analysis for apoptosis by TUNEL assay.
TUNEL staining was performed according to the manufacturer's protocols (in situ cell death detection kit; Roche Diagnostics, Boehringer Mannheim, Germany). Cells (1x10 6 /well) were individually plated into six-well plates and exposed to 1 µM vitexin and vitexin plus z-VAD or cyclosporine A (a mitochondrial membrane potential inhibitor) for 24 h. After treatment, cells were collected and fixed in 4% formaldehyde overnight, placed in 0.1% Triton X-100/PBS, washed with 0.1% PBS twice, then stained with 100 µl of terminal deoxynucleotidyl transferase-containing solution and incubated in the dark for 30 min at 37˚C. Following TUNEL staining, all samples were washed three times and resuspended in 0.5 ml of PBS containing PI (10 µg/ml) and DNase free-RNase A (200 µg/ml). TUNEL-positive cells were analyzed by flow cytometry. The median fluorescence intensity was quantified with CellQuest software (BD Biosciences) (21, 22) . TUNEL assays were performed in triplicate for three independent experiments.
Caspase activity determinations. Caspase activity in cell lysates was measured using the manufacturer's protocols (caspase-3, -7 and -9 colorimetric assay kits; R&D Systems Inc., Minneapolis, MN, USA). Cells were re-suspended in medium at an initial concentration of 5x10 6 cells and pelleted and re-suspended in 0, 50, 100, 200 and 400 µM of vitexin for 24 h. Cells were lysed in lysis buffer [50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 10 mM EGTA, 10 mM digitonin and 2 mM DTT]. The cell lysates (50 µg proteins) were incubated with caspase-3, -7 and -9 specific substrates (Ac-DEVD-pNA and Ac-LEHD-pNA) at 37˚C for 1 h. Caspase activity and absorbance were measured with an enzyme-linked immunosorbent assay reader at OD 405 (16, 23) . All results are from three independent experiments.
Measurement of mitochondrial membrane potential. Cells were seeded in 24-well cell culture plates at an initial concentration of 2x10 5 cells/ml and were maintained with 0, 50, 100, 200 and 400 µM of vitexin for 24 h. Flow cytometry was then used to determine the level of ∆Ψm. Following incubation, cells were harvested, washed twice by PBS, and then stained with 500 µl of 100 nM of DiOC 6 that was stored at -20˚C as a 1 µmol/l stock in DMSO for the level of ∆Ψm. Subsequently, cells were maintained in a dark room for 30 min at 37˚C and all samples were analyzed immediately by flow cytometry, as previously described (19, 24) .
Western blot analysis.
Western blot analysis to determine the levels of various proteins was performed as previously described (18, 19) . Cells were washed with PBS and lysed into the PRO-PREP™ protein extraction solution (iNtRON Biotechnology, Gyeonggi-do, Korea) before being placed in a 10-cm dish at an initial concentration of 1x10 7 cells and incubated with 200 µM of vitexin for 6,12,18 and 24 h. An equal amount of cell lysate was separated by 10% gel using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were electro-transferred to a nitrocellulose membrane using iBot Dry Blotting system (Invitrogen/ Life Technologies). The membrane was then blocked in 5% powdered non-fat milk in PBST solution (0.1% Tween-20 in PBS) for 1 h. The primary antibodies caspase-9, caspase-3 and Bcl-2 were diluted in blocking solution and then incubated with the membrane overnight. The membrane was then covered with an alkaline HRP conjugated secondary IgG antibody (goat anti-rabbit and goat anti-mouse) for 1 h. After incubating with the second antibody, the membranes were reacted with enhanced chemiluminescence (ECL) solution (Western blotting detection kit, Immobilon Western HRP substrate, Millipore, Billerica, MA, USA). Signals were detected by X-ray film (GE Healthcare, Piscataway, NJ, USA). β-actin was included as a loading control. The radiograms were scanned and the band density was quantified using NIH ImageJ program (Bethesda, MD, USA) (18) .
Statistical analysis. Data were expressed as the mean ± SD and differences between control and vitexin-treated groups were analyzed by Student's t-test. * p<0.05 was considered to indicate statistically significant differences. Fig. 2A indicate that the cells in the vitexin-treated and the control group differ significantly. Some of the cells detached from the surface and debris were also observed in the plate of the vitexin-treated group, but the control cells were well spread with flattened morphology (Fig. 2A) . To determine the growth inhibition effects of vitexin, cells were treated with different concentrations (50, 100, 200 and 400 µM) of vitexin for 24 h. Cell viability was determined by the MTT assay. Concentration-and time-dependent effects of vitexin are shown in Fig. 2B , and the viable cells were significantly reduced in the vitexin-treated U937 human leukemia cells. The concentration required to inhibit growth by 50% (IC 50 ) for U937 human leukemia cells was ~200.34 µM at 24 h. We suggest that vitexin reduced the proportion of viable U937 human leukemia cells in a concentration-and time-dependent manner.
Results

Effects of vitexin on morphological changes and cell viability of U937 human leukemia cells. The morphological changes shown in
Effects of DNA laddering fragmentation in U937 cells. DNA laddering provides evidence for a vitexin-induced apoptotic process characterized by DNA fragmentation. The agarose gel electrophoresis of DNA extracted from U937 cells treated with vitexin at various concentrations (200 and 400 µM) for 48 h was carried out and the results revealed that DNA fragmentation occurred in vitexin-treated U937 cells (Fig. 3A) . We also noted that pretreatment with z-VAD (a pan-caspase inhibitor) is likely to protect a vitexin-provoked DNA ladder of U937 cells. Similarly, TUNEL positive cells were also observed in U937 cells after exposure to 100, 200 and 400 µM of vitexin, and z-VAD attenuated vitexin-induced TUNEL positive cells in comparison to untreated control cells, as shown in Fig. 3B . Thus, vitexin concentration-dependently induced apoptosis by DNA fragmentation. Based on this finding, we suggest that vitexin-induced apoptotic death of U937 cells is correlated with caspase-dependent effects. -3, -7 , and -9 activities in U937 cells. We determined the roles of individual caspases in vitexin-induced apoptosis. In order to evaluate the effects of vitexin on the activities of caspase-3, -7 and -9 in U937 cells, caspase activity assays were applied to investigate related caspase activities. The results in Fig. 4A and B show that various concentrations (0, 50, 100, 200 and 400 µM) of vitexin promoted caspase-3, -7 ( Fig. 4A ) and caspase-9 (Fig. 4B ) activities in a concentration-dependent manner. We confirm that vitexin-induced apoptosis is mediated by activations of caspase-3, -7 and -9 signaling. Thus, we suggest that intrinsic apoptotic signaling contributed to vitexin-triggered apoptosis of U937 cells in vitro.
Effects of vitexin on the caspase
Effects of vitexin on mitochondrial membrane potential and its inhibitor (cyclosporine A) in U937 cells. Cells were treated with 50, 100, 200 and 400 µM of vitexin for 24 h. The alterations of ∆Ψm were determined by staining with DiOC 6 and then analyzed by flow cytometry, and representative data are shown in Fig. 5A demonstrating that vitexin decreased the level of ∆Ψm in U937 cells and this effect is a concentrationdependent response. To explore whether vitexin-induced apoptosis is mediated through mitochondrial depolarization, cyclosporine A (a ∆Ψm inhibitor) was used for measuring TUNEL positive cells. We found that cyclosporine A is able to Figure 4 . Effects of caspase-3, -7 and -9 activities on vitexin-treated U937 cells. The activities of (A) caspase-3, -7 and (B) caspase-9 in U937 cells after treatment with vitexin at various concentrations (0, 50, 100, 200 and 400 µM). Cells were then collected to add each substrate solution for caspase-3, -7 and -9 activity determination according to the manufacturer's instructions as described in Materials and methods. Data represent the mean ± SD of three experiments. *p<0.05 denotes statistically significant differences compared with untreated control. decrease vitexin-stimulated apoptosis in U937 cells as seen in Fig. 5B . We suggest that vitexin-induced apoptosis is involved in the mitochondrial signaling pathway.
Effects of vitexin on the levels of apoptosis-associated protein expression in U937 cells. We confirmed that vitexin-induced apoptosis is associated with mitochondria-dependent protein expressions. Our data indicate that vitexin promoted the expressions of cleaved caspase-3 and cleaved caspase-9 in U937 cells (Fig. 6A) . The Bcl-2 family proteins located on the mitochondrial membrane are important for suppression of mitochondrial manifestations of apoptosis (12, 16) . Fig. 6B shows that a decrease of Bcl-2 expression occurred in vitexin-treated U937 cells. Consequently, the induction of the mitochondrial pathway plays a central role in vitexin-induced apoptosis of U937 cells in vitro.
Discussion
Vitexin, a natural apigenin flavone glucoside, has been reported to exhibit antioxidative and anti-inflammatory properties, and to have growth inhibitory effects in human breast cancer cell lines (9, 25) , but few reports demonstrate its inhibitory effects on U937 human leukemia cells. In this study, we found that different concentrations (50, 100, 200, 400 µM) of vitexin significantly inhibited the growth of U937 human leukemia cells (Fig. 2B ). These data indicate that vitexin inhibited cell proliferation and induced apoptosis (Fig. 3) in the U937 human leukemia cells, and vitexin induced morphological changes ( Fig. 2A) and reduced the percentage of viable cells in the human U937 leukemia cell in a dose-and time-dependent manner.
It is well known that mitochondria are implicated as being a center mechanism and one of the apoptotic targets (26, 27) , and Bcl-2 family protein expression is likely to influence mitochondrial depolarization (28) . Consequently, the activations of caspase-9 and -3 are the key mediators of cell apoptosis (12, 28) . In the current study, we demonstrated that vitexin inhibited the levels of Bcl-2 ( Fig. 6B ) which led to the disruption of ∆Ψm (Fig. 5A ) in U937 cells. Importantly, vitexin stimulated caspase-9 and -3 activities (Fig. 4) and protein expressions (Fig. 6 ) in U937 cells. Pretreatment with z-VAD (a pan-caspase inhibitor) (Fig. 3A) and cyclosporine A (Fig. 5B) led to a decrease in vitexin-induced TUNEL positive cells, compared with cells treated alone. Hence, vitexin-provoked apoptosis could be inhibited via suppressing the mitochondrial and caspase-dependent pathways. Taken together, these results suggest the potential use of the antileukemia activity of vitexin and confirmed that vitexin may be used as a treatment for diseases such as leukemia. Our study is also in agreement with a previous study by Zhou et al addressing the biological activity and anticancer actions of vitexin in tumor cell lines (9) . In conclusion, the induction of apoptotic cell death by vitexin in U937 human leukemia cells was detected as an activation of caspase-3, -7 and -9 (Fig. 7) . Based on these experiments, we suggest that vitexin enhances the cytotoxicity and induces an apoptotic cell death in U937 human leukemia cells. 
